SBRT and Hypofractionation in Prostate Cancer

Opinion
Video

Prostate cancer specialists provide insights on stereotactic body radiation therapy (SBRT) and hypofractionation and their relationship to optimal rectal spacing.

Related Videos
Kevin Shee, MD, PhD, answers a question during a Zoom video interview
Daniel P. Petrylak, MD, answers a question during a video interview
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
Andrew L. Siegel, MD, answers a question during a Zoom video interview
Related Content
Dr. Agarwal on significance of ultra-low PSA levels achieved with apalutamide in mCSPC

Dr. Agarwal on significance of ultra-low PSA levels achieved with apalutamide in mCSPC

January 11th 2024
Article

Neeraj Agarwal, MD, discusses an analysis from the phase 3 TITAN trial that explored the correlation between PSA response and survival among patients with metastatic castration-sensitive prostate cancer receiving apalutamide.

Dr. Schwen on focal therapies for prostate cancer

Dr. Schwen on focal therapies for prostate cancer

January 11th 2024
Podcast

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Talazoparib plus enzalutamide approved in EU for mCRPC

Talazoparib plus enzalutamide approved in EU for mCRPC

January 9th 2024
Article

The combination is approved for the treatment of patients with metastatic castration-resistant prostate cancer, regardless of mutation status.

medical depiction of prostate cancer

Speaking of Urology: Liquid biopsy in prostate cancer

December 14th 2023
Podcast

In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.

medical depiction of prostate cancer treatment

Oral CYP11A1 inhibitor shows promise in mCRPC

January 5th 2024
Article

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

CMS payment rate established for ArteraAI prostate cancer test

CMS payment rate established for ArteraAI prostate cancer test

January 4th 2024
Article

The payment rate for the prostate cancer test went into effect on January 1, 2024.

© 2024 MJH Life Sciences

All rights reserved.